BioSpace News Archive

GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, today announced the results from phase I study of GFH312 (RIPK1 inhibitor) monotherapy will be presented as a poster at the 2023 ASCPT Meeting in Atlanta on March 22nd.

CB Scientific. Inc. today announced that it has finalized a comprehensive distribution agreement with newly formed Your Heart Protector Corp.

Ring Therapeutics today announced that it raised $86.5 million in Series C funding, bringing its total funds raised to date to $230 million.

Centogene N.V. today announced the appointment of Ian Rentsch as Chief Commercial Officer and General Manager - Pharma, who will join the Company on March 15, 2023.

Model N, Inc. announced the pricing of its offering of $220.0 million aggregate principal amount of convertible senior notes due 2028 in a private placement to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended, or the Securities Act.

GT Medical Technologies, Inc. announced its latest roster of ELITE Brain Tumor Centers that have received the distinction for completing 10 or more GammaTile Therapy procedures in 2022.

Candesant Biomedical today announced the acceptance of its pivotal SAHARA clinical trial data for its investigational targeted alkali thermolysis (TAT) Patch in a late-breaking oral presentation at the 2023 annual meeting of the American Academy of Dermatology (AAD), on March 18, 2023 in New Orleans, LA.

Positive high-level results from a planned interim analysis of the AEGEAN Phase III, placebo-controlled trial showed that treatment with AstraZeneca’s IMFINZI ®.

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Eric Shaff, President and Chief Executive Officer of Seres Therapeutics, will provide a corporate presentation at the Oppenheimer 33rd Annual Healthcare Conference on Wednesday, March 15, 2023 at 8:40 a.m. ET.

Coya Therapeutics, Inc. today announced it will host a conference call to present clinical data of Coya’s proprietary investigational biologic combination, COYA 302, in patients with Amyotrophic Lateral Sclerosis (ALS), on Tuesday, March 21, 2023 at 8:00am ET.